IGMS

IGM Biosciences

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 2

stock price surged significantly

Bearish Abandoned Baby

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About IGMS

Igm Biosciences, Inc.

A clinical-stage biotech company focused on creating and developing IgM antibodies

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

09/18/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

149

Fiscal Year Ends

12-31

Website

www.igmbio.com

Security Type

Common stock

Office address

325 E. Middlefield Road, Mountain View, CA 94043

Business

Introduction

IGM Biosciences, Inc., was incorporated in Delaware in August 1993 under the name Palingen, Inc. IGM Biosciences, Inc., is a biotechnology company developing IgM antibody therapies for the treatment of cancer.

Company Financials

EPS

IGMS has released its 2024 Q3 earnings. EPS was reported at -1.01, versus the expected -0.80, missing expectations. The chart below visualizes how IGMS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IGMS has released its 2024 Q4 earnings report, with revenue of 412.00K, reflecting a YoY change of -36.71%, and net profit of -36.65M, showing a YoY change of 39.62%. The Sankey diagram below clearly presents IGMS’s revenue sources and cost distribution.